Cold Urticaria Treatment Guidelines

First-Line Treatment

The British Journal of Dermatology recommends starting with second-generation H1 antihistamines, such as cetirizine, fexofenadine, loratadine, desloratadine, and levocetirizine, for all urticaria subtypes, including physical urticarias, due to their efficacy and safety profile 1, 2
Patients should be offered at least two different non-sedating antihistamines because individual responses vary significantly, as suggested by the British Journal of Dermatology 1, 2
If inadequate control occurs after 2-4 weeks, the dose of non-sedating antihistamines can be increased up to 4-fold the standard dose before switching to sedating alternatives, according to the British Journal of Dermatology and other guidelines 1, 3
Cetirizine reaches maximum concentration fastest, which may be advantageous when rapid symptom control is needed for cold exposure, as noted by the British Journal of Dermatology 1

Cyproheptadine functions as both an H1 antihistamine and an antiserotonergic agent, which may explain its superior efficacy in cold urticaria, as reported by the Journal of Allergy and Clinical Immunology 4
Cyproheptadine also possesses anticholinergic properties that may contribute to symptom control, according to the Journal of Allergy and Clinical Immunology 4

Diphenhydramine is highly sedating and impairs driving ability, leading to cognitive decline particularly in elderly patients, as warned by the Journal of Allergy and Clinical Immunology 4
Both cyproheptadine and diphenhydramine carry anticholinergic risks, including cognitive decline, especially concerning in elderly populations, as noted by the Journal of Allergy and Clinical Immunology 4

Adding H2 antihistamines, such as cimetidine, to H1 blockers may provide better urticaria control than H1 antihistamines alone, as suggested by the British Journal of Dermatology 1, 2
If symptoms remain uncontrolled despite 4-fold dosing of second-generation antihistamines and trial of cyproheptadine, consider omalizumab 300 mg every 4 weeks as next-line therapy, according to Praxis Medical Insights 3, 5

The British Journal of Dermatology advises against using first-generation antihistamines as monotherapy when second-generation agents haven't been tried at standard and increased doses first 1, 2
Avoid combining sedating antihistamines at bedtime with second-generation agents during the day, as this causes prolonged daytime drowsiness without meaningful additional H1 blockade, as warned by Praxis Medical Insights 3
The British Journal of Dermatology recommends avoiding NSAIDs and aspirin, as they can worsen urticaria through cyclooxygenase inhibition 1, 5
Minimize aggravating factors, including overheating, stress, and alcohol, as suggested by the British Journal of Dermatology and Praxis Medical Insights 1, 5
Exercise caution in elderly patients with anticholinergic agents like cyproheptadine and diphenhydramine due to cognitive decline risk, as noted by the Journal of Allergy and Clinical Immunology 4

Physical urticarias, such as cold urticaria, are chronic conditions that require ongoing treatment as long as the physical trigger remains part of the patient's environment, according to the British Journal of Dermatology guidelines 6, 7
Cold urticaria persists indefinitely and requires continuous prophylactic therapy rather than time-limited treatment, as stated by the British Journal of Dermatology 6, 7
The prognosis data showing 50% clearance at 6 months applies to ordinary chronic urticaria with spontaneous wheals, not physical urticarias like cold urticaria, which are stimulus-dependent, as noted by the British Journal of Dermatology 7